BioSpace News Archive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the fourth quarter and full year 2022.

Immix Biopharma, Inc. today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors.

Catalyst Pharmaceuticals, Inc., today provided preliminary 2022 fourth quarter and full year total revenues estimates, a forecast of 2023 total revenue expectations, and a corporate update.

Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101

Replimune Group, Inc. today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.

Onconova Therapeutics, Inc. today announced that the second of two evaluable participants in an investigator-initiated Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) achieved a complete response of all cancerous skin lesions following 4 treatment cycles and remains on oral rigosertib.

Pliant Therapeutics, Inc. today announced senior management’s participation in the following investor events in February.

BioSig Technologies, Inc. today announced the retirement of chief financial officer Steve Chaussy following a distinguished career with the Company, and has named Steve Buhaly as his successor.

Orchestra BioMed Holdings, Inc. announced the addition of several highly accomplished industry veterans to its senior leadership team.

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, February 16, 2023, at 4:30 p.m. Eastern Time (ET) to review its 2022 financial results and provide a business update.